NCT07051603View on ClinicalTrials.gov

SAL0140 Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in a Healthy Chinese Population

PHASE1RecruitingINTERVENTIONAL
Enrollment

82

Participants

Timeline

Start Date

June 9, 2025

Primary Completion Date

January 31, 2026

Study Completion Date

February 28, 2026

Conditions
Uncontrolled Hypertension
Interventions
DRUG

SAL0140

In this part, SAL0140 tablets will be administered as a single or multiple oral dose.

DRUG

SAL0140 placebo

In this part, SAL0140 placebo tablets will be administered as a single or multiple oral dose.

Trial Locations (1)

510515

RECRUITING

Nanfang Hospital of Southern Medical University, Guangzhou

All Listed Sponsors
lead

Shenzhen Salubris Pharmaceuticals Co., Ltd.

INDUSTRY